Log in to save to my catalogue

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinom...

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinom...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2824694918

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

About this item

Full title

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2023-07, Vol.402 (10397), p.185-195

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Immune checkpoint inhibitors are the standard of care for first-line treatment of patients with metastatic renal cell carcinoma, yet optimised treatment of patients whose disease progresses after these therapies is unknown. The aim of this study was to determine whether adding atezolizumab to cabozantinib delayed disease progression and prolonged s...

Alternative Titles

Full title

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2824694918

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2824694918

Other Identifiers

ISSN

0140-6736,1474-547X

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(23)00922-4

How to access this item